Finally the bias towards a more cellular response by the liposomes could also be attributed to the presence of DOPE in the liposomes. DOPE, a neutral pH-sensitive lipid, is capable of improving delivery of CpG into the cytosol following APC uptake [46]. Endosomal escape is crucial for MHC I presentation of the antigen and the induction of CTL responses. It has been reported that liposomes

complexed with antigen and either CpG or poly(I:C), which binds to TLR3 that is also expressed intracellularly, are capable of cross priming CD8+ T cells [47]. Whether this is also the case after ID immunisation with our liposomes requires further investigation, but the elevated IFN-γ production is a first indication that a CTL response could be induced [48]. In conclusion, the advantage of co-encapsulation of AP24534 check details antigen and TLR ligand in cationic liposomes is their potency to steer the immune bias. This depends on the type of TLR ligand used, as CpG, binding to the intracellular TLR9, induced the production of IgG2a antibodies and a potent cellular immune response after ID immunisation, whereas PAM, ligand of extracellular TLR2, did not. This research was performed under the framework of

TI Pharma project number D5-106 “vaccine delivery: alternatives for conventional multiple injection vaccines”. The authors thank Bram Slütter for critically reading the manuscript. “
“In June 2009, WHO declared the first influenza pandemic in over 40 years. The emergence of this new influenza virus initiated a robust and rapid response from public health partners around the world, including the research-based vaccine industry. As the 2009 A(H1N1) virus enters its post-pandemic ADP ribosylation factor phase, international institutions, national governments and individual manufacturers are conducting reviews to identify which aspects of the response were successful, and which can be improved. As part of this global assessment process, the international and European organizations that represent the world’s major influenza

vaccine manufacturers (the IFPMA IVS taskforce and EVM respectively) have worked together to compile an industry perspective. This is intended to complement the reviews conducted by other organizations, and ultimately to help inform future preparedness activities. Vaccines are a crucial tool in the fight against pandemic influenza, and consequently the vaccine industry has an essential role to play when called on by public health authorities. In answering this call, the manufacturers’ role is clear: the rapid development, production and supply of safe and effective pandemic vaccines to enable the immunization of local populations. However, fulfilling this role is challenging. Influenza vaccine manufacture is complex and time consuming, and requires specialist facilities and highly trained personnel.